Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 11,500.00
Ask: 12,200.00
Change: 0.00 (0.00%)
Spread: 700.00 (6.087%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI) - Amendment

22 May 2014 07:00

RNS Number : 7584H
Goldman Sachs & Co.
21 May 2014
 



 

Amendment - due to the amendment of Equity and Option transactions, the disclosure made on 19 May for dealings on 16 May has been updated. Sections 2(a), 3(a), 3(c)(ii) and Supplemental Form have been updated.

 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

(GS) GOLDMAN, SACHS & CO.

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

ASTRAZENECA PLC

(d) Date position held/dealing undertaken:

16 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

USD 0.25 ordinary and ADRs

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

11,313*

0.00*

299,900

0.02

(2) Derivatives (other than options):

160

0.00

0

0.00

(3) Options and agreements to purchase/sell:

2,375,400*

0.18*

592,500*

0.04*

 

TOTAL:

2,386,873*

0.18*

892,400*

0.07*

*(GS) GOLDMAN, SACHS & CO. resulting position includes changes resulting from positions relating to the ad-hoc GSCO exemption that were previously treated as non-exempt; including 11,020 equity, 189,400 long options and 169,900 short options.

 

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

ADR

Purchase

1,100

65.0000 USD

ADR

Purchase

2,000

70.0000 USD

ADR

Purchase

2,800

72.5000 USD

ADR

Purchase

100

80.0000 USD

ADR

Purchase

100

80.0500 USD

ADR

Purchase

100

80.2600 USD

ADR

Purchase

200

80.2600 USD

ADR

Purchase

200

80.2600 USD

ADR

Purchase

100

80.2700 USD

ADR

Purchase

100

80.2800 USD

ADR

Purchase

100

80.2800 USD

ADR

Purchase

100

80.2800 USD

ADR

Purchase

100

80.2800 USD

ADR

Purchase

200

80.2900 USD

ADR

Purchase

100

80.2900 USD

ADR

Purchase

100

80.2900 USD

ADR

Purchase

100

80.2900 USD

ADR

Purchase

200

80.2900 USD

ADR

Purchase

100

80.2900 USD

ADR

Purchase

100

80.2900 USD

ADR

Purchase

400

80.3000 USD

ADR

Purchase

100

80.3000 USD

ADR

Purchase

100

80.3000 USD

ADR

Purchase

100

80.3000 USD

ADR

Purchase

100

80.3100 USD

ADR

Purchase

100

80.3100 USD

ADR

Purchase

100

80.3100 USD

ADR

Purchase

100

80.3100 USD

ADR

Purchase

100

80.3100 USD

ADR

Purchase

50

80.3200 USD

ADR

Purchase

100

80.3200 USD

ADR

Purchase

50

80.3200 USD

ADR

Purchase

50

80.3200 USD

ADR

Purchase

400

80.3700 USD

ADR

Purchase

400

80.3800 USD

ADR

Purchase

400

80.3800 USD

ADR

Purchase

100

80.4100 USD

ADR

Purchase

100

80.4100 USD

ADR

Purchase

300

80.4200 USD

ADR

Purchase

400

80.4200 USD

ADR

Purchase

100

80.4400 USD

ADR

Purchase

100

80.4700 USD

ADR

Purchase

100

80.4700 USD

ADR

Purchase

100

80.4700 USD

ADR

Purchase

100

80.4900 USD

ADR

Purchase

400

80.5000 USD

ADR

Purchase

100

80.5000 USD

ADR

Purchase

500

80.5000 USD

ADR

Purchase

300

80.5000 USD

ADR

Purchase

400

80.5000 USD

ADR

Purchase

100

80.5200 USD

ADR

Purchase

300

80.5500 USD

ADR

Purchase

100

80.5700 USD

ADR

Purchase

100

80.5800 USD

ADR

Purchase

100

80.5900 USD

ADR

Purchase

200

80.6000 USD

ADR

Purchase

100

80.6100 USD

ADR

Purchase

200

80.6100 USD

ADR

Purchase

200

80.6200 USD

ADR

Purchase

300

80.6200 USD

ADR

Purchase

100

80.6400 USD

ADR

Purchase

200

80.6400 USD

ADR

Purchase

300

80.6400 USD

ADR

Purchase

100

80.6500 USD

ADR

Purchase

100

80.6500 USD

ADR

Purchase

100

80.6500 USD

ADR

Purchase

100

80.6500 USD

ADR

Purchase

200

80.6600 USD

ADR

Purchase

300

80.6700 USD

ADR

Purchase

200

80.6800 USD

ADR

Purchase

100

80.6900 USD

ADR

Purchase

400

80.7000 USD

ADR

Purchase

100

80.7000 USD

ADR

Purchase

100

80.7100 USD

ADR

Purchase

300

80.7100 USD

ADR

Purchase

100

80.7200 USD

ADR

Purchase

200

80.7200 USD

ADR

Purchase

100

80.7300 USD

ADR

Purchase

300

80.7300 USD

ADR

Purchase

300

80.7400 USD

ADR

Purchase

200

80.7500 USD

ADR

Purchase

100

80.7500 USD

ADR

Purchase

100

80.7500 USD

ADR

Purchase

300

80.7500 USD

ADR

Purchase

100

80.7600 USD

ADR

Purchase

200

80.7600 USD

ADR

Purchase

300

80.7600 USD

ADR

Purchase

100

80.7700 USD

ADR

Purchase

94

80.8000 USD

ADR

Purchase

100

80.8000 USD

ADR

Purchase

100

80.8100 USD

ADR

Purchase

100

80.8200 USD

ADR

Purchase

300

80.8200 USD

ADR

Purchase

100

80.8200 USD

ADR

Purchase

100

80.8300 USD

ADR

Purchase

46

80.8300 USD

ADR

Purchase

100

80.8400 USD

ADR

Purchase

100

80.8400 USD

ADR

Purchase

107

80.8400 USD

ADR

Purchase

293

80.8400 USD

ADR

Purchase

300

80.8500 USD

ADR

Purchase

100

80.8500 USD

ADR

Purchase

700

80.8500 USD

ADR

Purchase

100

80.8500 USD

ADR

Purchase

133

80.8500 USD

ADR

Purchase

200

80.8600 USD

ADR

Purchase

600

80.8700 USD

ADR

Purchase

100

80.9000 USD

ADR

Purchase

100

80.9000 USD

ADR

Purchase

100

80.9000 USD

ADR

Purchase

100

80.9000 USD

ADR

Purchase

100

80.9000 USD

ADR

Purchase

600

80.9000 USD

ADR

Purchase

300

80.9100 USD

ADR

Purchase

500

80.9200 USD

ADR

Purchase

57

80.9500 USD

ADR

Purchase

100

81.0000 USD

ADR

Purchase

100

81.0000 USD

ADR

Purchase

100

81.0000 USD

ADR

Purchase

100

81.0300 USD

ADR

Purchase

100

81.0300 USD

ADR

Purchase

400

81.1100 USD

ADR

Sale

600

67.5000 USD

ADR

Sale

39,400

67.5000 USD

ADR

Sale

200

75.0000 USD

ADR

Sale

500

79.7500 USD

ADR

Sale

100

79.8400 USD

ADR

Sale

100

79.9100 USD

ADR

Sale

100

80.1500 USD

ADR

Sale

200

80.1600 USD

ADR

Sale

100

80.2200 USD

ADR

Sale

100

80.2200 USD

ADR

Sale

500

80.2200 USD

ADR

Sale

400

80.2200 USD

ADR

Sale

100

80.2300 USD

ADR

Sale

200

80.2300 USD

ADR

Sale

100

80.2300 USD

ADR

Sale

100

80.2300 USD

ADR

Sale

100

80.2300 USD

ADR

Sale

100

80.2400 USD

ADR

Sale

100

80.2500 USD

ADR

Sale

68

80.2600 USD

ADR

Sale

100

80.2900 USD

ADR

Sale

200

80.2900 USD

ADR

Sale

36

80.2900 USD

ADR

Sale

100

80.2900 USD

ADR

Sale

100

80.3200 USD

ADR

Sale

100

80.3300 USD

ADR

Sale

100

80.3300 USD

ADR

Sale

100

80.3500 USD

ADR

Sale

100

80.3600 USD

ADR

Sale

20

80.4500 USD

ADR

Sale

180

80.4500 USD

ADR

Sale

800

80.4500 USD

ADR

Sale

100

80.4600 USD

ADR

Sale

100

80.4600 USD

ADR

Sale

300

80.4600 USD

ADR

Sale

200

80.4600 USD

ADR

Sale

200

80.4700 USD

ADR

Sale

200

80.4900 USD

ADR

Sale

100

80.5200 USD

ADR

Sale

100

80.5200 USD

ADR

Sale

300

80.5300 USD

ADR

Sale

100

80.5900 USD

ADR

Sale

200

80.6000 USD

ADR

Sale

300

80.6100 USD

ADR

Sale

100

80.6200 USD

ADR

Sale

100

80.6200 USD

ADR

Sale

100

80.6200 USD

ADR

Sale

100

80.6400 USD

ADR

Sale

200

80.6400 USD

ADR

Sale

100

80.6400 USD

ADR

Sale

100

80.6400 USD

ADR

Sale

100

80.6400 USD

ADR

Sale

300

80.6400 USD

ADR

Sale

100

80.6500 USD

ADR

Sale

100

80.6500 USD

ADR

Sale

80

80.6500 USD

ADR

Sale

100

80.6500 USD

ADR

Sale

100

80.6500 USD

ADR

Sale

100

80.6500 USD

ADR

Sale

200

80.6500 USD

ADR

Sale

100

80.6500 USD

ADR

Sale

100

80.6700 USD

ADR

Sale

100

80.6800 USD

ADR

Sale

400

80.6800 USD

ADR

Sale

100

80.6800 USD

ADR

Sale

100

80.6900 USD

ADR

Sale

100

80.6900 USD

ADR

Sale

100

80.6900 USD

ADR

Sale

100

80.6900 USD

ADR

Sale

100

80.6900 USD

ADR

Sale

100

80.7000 USD

ADR

Sale

8

80.7000 USD

ADR

Sale

9

80.7000 USD

ADR

Sale

8

80.7000 USD

ADR

Sale

8

80.7000 USD

ADR

Sale

200

80.7000 USD

ADR

Sale

71

80.7000 USD

ADR

Sale

9

80.7000 USD

ADR

Sale

8

80.7000 USD

ADR

Sale

100

80.7100 USD

ADR

Sale

300

80.7100 USD

ADR

Sale

200

80.7100 USD

ADR

Sale

400

80.7200 USD

ADR

Sale

200

80.7200 USD

ADR

Sale

100

80.7300 USD

ADR

Sale

100

80.7300 USD

ADR

Sale

100

80.7500 USD

ADR

Sale

300

80.7600 USD

ADR

Sale

300

80.7600 USD

ADR

Sale

300

80.7800 USD

ADR

Sale

300

80.7800 USD

ADR

Sale

200

80.7800 USD

ADR

Sale

100

80.7800 USD

ADR

Sale

100

80.7900 USD

ADR

Sale

400

80.7900 USD

ADR

Sale

100

80.7900 USD

ADR

Sale

86

80.8100 USD

ADR

Sale

400

80.8100 USD

ADR

Sale

100

80.8200 USD

ADR

Sale

100

80.8200 USD

ADR

Sale

100

80.8400 USD

ADR

Sale

275

80.8400 USD

ADR

Sale

100

80.8600 USD

ADR

Sale

100

80.8600 USD

ADR

Sale

200

80.8600 USD

ADR

Sale

100

80.8600 USD

ADR

Sale

100

80.8600 USD

ADR

Sale

300

80.8700 USD

ADR

Sale

300

80.8700 USD

ADR

Sale

100

80.8800 USD

ADR

Sale

100

80.8800 USD

ADR

Sale

100

80.8800 USD

ADR

Sale

100

80.8800 USD

ADR

Sale

300

80.8800 USD

ADR

Sale

200

80.8900 USD

ADR

Sale

700

80.9000 USD

ADR

Sale

129

80.9000 USD

ADR

Sale

200

80.9000 USD

ADR

Sale

200

80.9000 USD

ADR

Sale

100

80.9000 USD

ADR

Sale

100

80.9300 USD

ADR

Sale

200

80.9300 USD

ADR

Sale

300

80.9500 USD

ADR

Sale

100

80.9800 USD

ADR

Sale

100

80.9800 USD

ADR

Sale

100

81.0000 USD

ADR

Sale

200

81.0000 USD

ADR

Sale

100

81.0000 USD

ADR

Sale

100

81.0100 USD

ADR

Sale

200

81.0100 USD

ADR

Sale

300

81.0500 USD

ADR

Sale

100

81.1000 USD

 

 

 

Class of relevant security

Purchases/sales

Total number of securities

ADR

Purchases

27,080

ADR

Sales

60,995

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

USD 0.25 ordinary

Call Option

200

75.0000 USD

USD 0.25 ordinary

Call Option

600

67.5000 USD

USD 0.25 ordinary

Call Option

1,100

65.0000 USD

USD 0.25 ordinary

Call Option

2,000

70.0000 USD

USD 0.25 ordinary

Call Option

2,800

72.5000 USD

USD 0.25 ordinary

Put Option

1,100

70.0000 USD

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES

 

 

Date of disclosure:

21 May 2014

Contact name:

Helen-Marie Moloney and Christopher Owers

Telephone number:

+44(20) 7774 8019 / +44(20) 7552 1461

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

SUPPLEMENTAL FORM 8(OPEN POSITIONS)

 

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENT TO

PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

Identity of the person whose open positions are being disclosed:

(GS) GOLDMAN, SACHS & CO.

Name of offeror/offeree in relation to whose relevant securities disclosure relates:

ASTRAZENECA PLC

 

 

2. OPTIONS AND DERIVATIVES

 

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

USD 0.25 ordinary

Call Option

Sold

100

75.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Call Option

Sold

200

45.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

200

80.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Purchased

300

72.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

500

80.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

600

60.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

600

70.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Call Option

Sold

800

67.5000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Purchased

800

67.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Sold

1,000

90.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

1,100

70.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Purchased

1,200

72.5000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Sold

1,300

62.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

1,300

67.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

1,600

65.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

1,600

67.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

1,700

62.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

1,800

70.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

1,800

75.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Purchased

2,000

55.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

2,400

75.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

2,400

77.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

2,600

67.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

2,700

57.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

2,800

65.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Call Option

Purchased

2,900

77.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Sold

3,100

60.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Call Option

Purchased

3,100

75.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

3,300

75.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

3,300

85.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

3,500

72.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

4,600

65.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

5,400

75.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

7,100

72.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Sold

7,400

70.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

9,400

80.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

11,100

65.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

15,400

72.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Sold

15,800

62.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

16,600

70.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

18,100

60.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

21,900

70.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

32,500

80.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

33,300

60.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

39,400

67.5000 USD

AMER

17/05/2014

USD 0.25 ordinary

Call Option

Purchased

43,200

70.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

100,000

70.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

100,000

75.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

100,000

77.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

100,000

80.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

138,300

70.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

153,900

80.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

165,100

60.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

200,000

40.0000 GBP

AMER

20/06/2014

USD 0.25 ordinary

Call Option

Purchased

200,000

40.0000 GBP

AMER

20/06/2014

USD 0.25 ordinary

Call Option

Purchased

200,000

40.0000 GBP

AMER

20/06/2014

USD 0.25 ordinary

Call Option

Purchased

237,800

65.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

338,800

70.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Purchased

100

35.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

100

40.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Purchased

100

40.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Purchased

100

47.5000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Purchased

200

30.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

200

37.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

300

70.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

300

75.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

500

52.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

600

57.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

600

65.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

900

27.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

900

32.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

900

70.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

1,000

55.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

1,000

60.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

1,000

60.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Put Option

Sold

1,200

67.5000 USD

AMER

18/10/2014

USD 0.25 ordinary

Put Option

Sold

1,200

72.5000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Sold

1,300

40.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

2,100

30.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Purchased

2,100

50.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

2,100

65.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Put Option

Sold

2,300

52.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

2,400

35.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Purchased

2,600

57.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Sold

2,600

65.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

3,100

67.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

3,600

70.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Put Option

Sold

3,900

52.5000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Sold

4,100

70.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Purchased

4,300

60.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Sold

4,700

42.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

5,000

25.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

5,100

47.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

5,200

45.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

5,900

62.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Purchased

6,400

50.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

7,100

65.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

7,500

60.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

7,600

67.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

8,600

55.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

10,000

55.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

10,400

62.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

11,600

57.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

16,300

62.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

25,000

38.0000 GBP

EURO

20/06/2014

USD 0.25 ordinary

Put Option

Purchased

40,000

65.0000 USD

AMER

17/05/2014

USD 0.25 ordinary

Put Option

Sold

48,000

62.5000 USD

AMER

17/05/2014

USD 0.25 ordinary

Put Option

Sold

50,000

70.0000 USD

AMER

17/05/2014

USD 0.25 ordinary

Put Option

Sold

85,600

65.0000 USD

AMER

17/05/2014

USD 0.25 ordinary

Put Option

Sold

92,500

62.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Sold

100,000

67.5000 USD

AMER

17/05/2014

USD 0.25 ordinary

Swap

Purchased

160

0.0000

N/A

08/04/2015

 

 

3. AGREEMENTS TO PURCHASE OR SELL

 

Full details should be given so that the nature of the interest or position can be fully understood:

 

It is not necessary to provide details on a Supplement form (Open Positions) with regard to contracts for differences ("CFD") or spread bets

 

 The currency of all pieces and other monetary amounts should be stated.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOQKDDDCBKDCPB
Date   Source Headline
16th Sep 20227:00 amRNSNirsevimab recommended for approval in EU by CHMP
5th Sep 20227:05 amRNSForxiga approved in China for CKD
5th Sep 20227:00 amRNSImfinzi approved in US for biliary tract cancer
1st Sep 20223:00 pmRNSTotal Voting Rights
30th Aug 20221:00 pmRNSEvusheld approved for COVID-19 in Japan
30th Aug 20227:01 amRNSFarxiga shows CV mortality benefit across EF range
30th Aug 20227:00 amRNSFarxiga reduced risk of CV death or worsening HF
25th Aug 20227:10 amRNSUltomiris approved in Japan for gMG
25th Aug 20227:05 amRNSTagrisso approved in Japan for early lung cancer
25th Aug 20227:00 amRNSLynparza approved in Japan for early breast cancer
16th Aug 20227:00 amRNSLynparza granted FDA priority review for PROpel
15th Aug 20227:00 amRNSEnhertu improved PFS in mBC in DESTINY-Breast02
12th Aug 20227:00 amRNSEnhertu approved in US for HER2-mutant NSCLC
11th Aug 20227:00 amRNSAcquisition of TeneoTwo completed
8th Aug 20227:10 amRNSEnhertu approved in the US for HER2-low mBC
4th Aug 20227:00 amRNSLynparza approved in EU for early breast cancer
1st Aug 20225:00 pmRNSDirector/PDMR Shareholding
1st Aug 20223:05 pmRNSDirector/PDMR Shareholding
1st Aug 20223:00 pmRNSTotal Voting Rights
29th Jul 20227:01 amRNSChair succession
29th Jul 20227:00 amRNSHalf-year Report
25th Jul 20227:10 amRNSTezspire recommended for EU approval in asthma
25th Jul 20227:05 amRNSUltomiris recommended for EU approval for gMG
25th Jul 20227:00 amRNSEnhertu granted Priority Review for HER2-low mBC
19th Jul 20227:00 amRNSEnhertu approved in EU for HER2-positive mBC
5th Jul 20227:00 amRNSAstraZeneca to acquire TeneoTwo and T cell engager
1st Jul 20223:00 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSImfinzi improved pCR in resectable lung cancer
27th Jun 20227:05 amRNSEnhertu recommended for breast cancer EU approval
27th Jun 20227:00 amRNSLynparza recommended in EU for early breast cancer
21st Jun 20227:00 amRNSEplontersen Ph III trial met co-primary endpoints
6th Jun 20227:00 amRNSEnhertu efficacy results in HER2-low breast cancer
1st Jun 20223:00 pmRNSBlock listing Interim Review
1st Jun 20223:00 pmRNSTotal Voting Rights
20th May 20224:00 pmRNSDirector/PDMR Shareholding
9th May 20221:00 pmRNSAppointment of joint corporate brokers
6th May 20224:00 pmRNSDirector/PDMR Shareholding
5th May 20227:10 amRNSEnhertu approved in US for 2L HER2+ breast cancer
5th May 20227:05 amRNSFarxiga HFpEF Phase III trial met primary endpoint
5th May 20227:00 amRNSUltomiris NMOSD Ph. III trial met primary endpoint
4th May 20227:00 amRNSImfinzi combo granted Priority Review for BTC
3rd May 20223:00 pmRNSTotal Voting Rights
29th Apr 20225:30 pmRNSResult of AGM
29th Apr 20227:05 amRNSAstraZeneca plans new R&D centre in Massachusetts
29th Apr 20227:00 amRNSFirst quarter 2022 results
28th Apr 20227:00 amRNSUltomiris approved in the US for adults with gMG
27th Apr 20227:00 amRNSEnhertu granted BTD for HER2-low breast cancer
25th Apr 20227:00 amRNSTremelimumab US Priority Review for Imfinzi combo
19th Apr 20227:00 amRNSEnhertu granted Priority Review for HER2m NSCLC
1st Apr 20223:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.